2022年第45届美国圣安东尼奥乳腺癌研讨会（SABCS）将于美国中部时间12月6~10日以线上及线下的形式召开！SABCS是世界上规模最大、最具影响力的乳腺癌会议，预计将有来自80多个国家的8000名人员参会。本次研讨会旨在向国际学术界、医师和研究人员提供有关乳腺癌和癌前期乳腺疾病的实验生物学、病因学、预防、诊断和治疗等方面最前沿的信息。
日前，大会公布了本次会议的详细日程，【肿瘤资讯】为您整理了相关“Ongoing Trials Poster Sessions”专场中国学者报告主题及壁报内容，以了解我国乳腺领域大咖们的最新研究方向，为肿瘤医生带来新启发！
Ongoing Trials Poster Session 1
Antibody-Drug Conjugates
抗体-药物偶联物
摘要号：OT1-03-02
中文标题：SKB264用于既往接受过治疗的转移性三阴性乳腺癌患者的疗效和安全性——一项Ⅱ期研究
原标题：Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study
作者：Yin Y, Wu X, Ouyang Q, Yan M, Song L, Liu Y, Tong Z, Geng C, Yu G, Wang X, Cheng Y, Zhao W, Li Q, Diao Y, Liu G, Ge J, Li J.
Advanced TNBC
晚期三阴性乳腺癌
摘要号：OT1-05-02
中文标题：信迪利单抗联合安罗替尼、节拍化疗治疗晚期三阴性乳腺癌的疗效和安全性（SPACE）——一项单臂、多中心Ⅱ期试验的初步结果
原标题：Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): preliminary results of a single-arm, multicenter phase II trial
作者：Li H, Tan Q, Sun S, Zhou D, Yu B, Su M, Li B, Fang S, Qiang L, Ren G, Bu B, Yin S, Man X, Qiu P, Wang X, Li C, Cao F, Shao Q, Han D, Song L, Fan B, Zhang B, Xu L, Zhao X, Liao Y, Xie X, Liu L.
Breast Conserving Surgery
保乳手术
摘要号：OT1-12-03
中文标题：基于定位引导+多排螺旋CT三维重建的精准保乳术——一项单中心、前瞻性队列研究
原标题：Precision breast conserving surgery with the guidance of localization combined with multidetector CT 3-dimensional image reconstruction: a single center, prospective, cohort study
作者：Xia Y, Cao D, Yang L, Zheng M, Weng M, Bachelor KS, Wang R, Zhao M, Xie H, Wang S.
CDK4/6 Inhibitors
CDK4/6抑制剂
摘要号：OT1-14-01
中文标题：哌柏西利治疗局晚期或转移性乳腺癌的有效性和安全性——一项多中心、真实世界研究
原标题：Efficiency and safety of palbociclib in patients with locally advanced or metastatic breast cancer: a muti-center real world study
作者：Yin Y, Huang X, Li W, Wu X, Hua Y, Sung C.
Ongoing Trials Poster Session 2
Immune Checkpoint Inhibitors
免疫检查点抑制剂
摘要号：OT2-08-01
中文标题：AK105联合安罗替尼、白蛋白紫杉醇一线治疗晚期三阴性乳腺癌的疗效和安全性——一项前瞻性Ⅱ期研究
原标题：A prospective phase 2 study on efficacy and safety of AK105, anlotinib combined with nab-paclitaxel (nab-P) as a first-line therapy in patients (pts) with advanced triple-negative breast cancer (TNBC)
作者：Sun T, Zhang L.
Long-term Adjuvant Pan-HER TKI
泛HER酪氨酸激酶抑制剂长期辅助治疗
摘要号：OT2-14-01
中文标题：高危HER2阳性早期乳腺癌患者曲妥珠单抗相关方案辅助治疗后应用吡咯替尼——一项多中心Ⅱ期试验
原标题：Pyrotinib after trastuzumab-based adjuvant therapy in high-risk early human epidermal growth factor receptor 2-positive breast cancer: a multicenter phase 2 trial
作者：Cao F, Ma Z, Hu G, Zhu X, Li S, Chen S, Chen B, Li Z, Wu W, Ji X, Shu J, Tao D, Hu X, Zheng M, Wang O, Feng Q, Hao J, Li X.
Monoclonal Antibodies
单克隆抗体
摘要号：OT2-16-04
中文标题：KN026联合多西他赛方案用于HER2阳性早期或局晚期乳腺癌新辅助治疗——一项单臂、多中心、Ⅱ期研究
原标题：KN026 in combination with docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer: A single arm, multicenter, phase 2 study
作者：Wu J, Yang B, Ma L, Zhang M, Wang K, Chen Y, Fan Z, Zhang J, Xia S.
Neoadjuvant Chemotherapy
新辅助化疗
摘要号：OT2-18-01
中文标题：白蛋白紫杉醇序贯剂量密集型化疗方案（表柔比星/环磷酰胺）用于三阴性乳腺癌新辅助化疗：一项开放标签、单臂Ⅱ期研究
原标题：Nab-paclitaxel followed by dose-dense epirubicin/cyclophosphamide in neoadjuvant chemotherapy for triple-negative breast cancer: an open-label, single-arm phase II study
作者：Liu Y, Fan L, Shao Z-M, Wang Z-H.
摘要号：OT2-18-03
中文标题：安罗替尼联合以白蛋白紫杉醇为基础的化疗方案用于HER2阴性乳腺癌新辅助治疗——一项前瞻性、单臂、单中心、Ⅱ期临床研究
原标题：Neoadjuvant anlotinib plus nab-paclitaxel based chemotherapy in patients with HER2-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study
作者：Fan J, Wang T, Meng H, Li S, Kong J, Wang Y.
Neoadjuvant Therapy
新辅助治疗
摘要号：OT2-22-01
中文标题：表柔比星+环磷酰胺+吡咯替尼序贯多西他赛+曲妥珠单抗+吡咯替尼方案用于Ⅱ~Ⅲ期HER2阳性乳腺癌新辅助治疗——一项单臂、多中心Ⅱ期试验
原标题：Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial
作者：Shi Q, Qi X, Tang P, Fan L, Chen L, Wang S, Zhang G, Wang M, Che H, Lv P, Chen D, Hu J, Li Q, Zhang Y, Yu Q, Yang K, Zhong Y, Chen C, Zhou Z, Qian L, Zhang J, Ma M, Sun Y, Liu J, Zhang Y, Jiang J.
Ongoing Trials Poster Session 3
Surgery – Reconstruction
手术-乳房重建
摘要号：OT3-21-01
中文标题：机器人辅助下（基于达芬奇SP®单孔手术系统）保留乳头乳晕的乳房切除+即刻乳房再造——一项初探性研究
原标题：A pilot study of robot-assisted nipple-sparing mastectomy followed by immediate breast reconstruction using da Vinci SP ® single-port system
作者：Kuo W-L, Chu C-H, Huang J-j.
Targeted-HER2
抗HER2靶向治疗
摘要号：OT3-25-02
中文标题：伊尼妥单抗联合吡咯替尼及化疗用于既往接受过治疗的HER2阳性转移性乳腺癌患者——一项单臂、多中心Ⅱ期临床试验
原标题：Inetetamab combined with pyrotinib and Chemotherapy in Pretreated Patients with HER2-positive metastatic breast cancer，a single arm，multicenter phase II clinical trial
作者：Zhao J, Cai Y, Ding L, Yang Y, Zou G, Yao H, Wang Y.
TNBC Subtyping
TNBC亚型
摘要号：OT3-27-01
中文标题：基于TNBC亚型分析结果对既往接受过多线治疗的转移性三阴性乳腺癌患者开展精准治疗——一项多中心、Ⅱ期、伞式研究（FUTURE试验）
原标题：Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: a multicenter, phase 2, umbrella, FUTURE trial
作者：Shao Z-M, Wang Z-H, Jiang Y-Z, Liu Y, Zhu X-Z, Xiao Y, Wu S-Y, Zuo W-J, Yu Q, Cao A-Y, Li J-J, Yu K-D, Liu G-Y, Wu J, Sun T, Cui J, Lv Z, Li H-P, Zhu X-Y.
Tyrosine Kinase Inhibitors
酪氨酸激酶抑制剂
摘要号：OT3-29-01
中文标题：安罗替尼联合吡咯替尼和卡培他滨治疗HER2阳性转移性乳腺癌：一项Ⅰb/Ⅱ期研究
原标题：A Phase Ib/II Study of anlotinib combined with pyrotinib and capecitabine for HER2-positive metastatic breast cancer
作者：Luo T, Zhong X, Chen J.
资料来源（部分研究无壁报图片展示）：
https://www.sabcs.org/Program/Schedule-at-a-Glance
排版编辑：肿瘤资讯-Paine
苏公网安备32059002004080号
